Clicky

Amylyx Pharmaceuticals, Inc.(AMLX)

Description: Amylyx Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company is developing AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.


Keywords: Pharmaceutical Life Sciences Alzheimer's Disease Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Nervous System Neurodegenerative Disease Apoptosis Sodium Phenylbutyrate

Home Page: amylyx.com

AMLX Technical Analysis

43 Thorndike Street
Cambridge, MA 02141
United States
Phone: 617 682 0917


Officers

Name Title
Mr. Joshua B. Cohen Co-Founder, Co-CEO & Director
Mr. Justin B. Klee Co-Founder, Co-CEO & Director
Mr. James M. Frates M.B.A. Chief Financial Officer
Ms. Margaret M. Olinger M.B.A Global Head of Commercial & Chief Commercial Officer
Mr. Tom Holmes Chief Technical Operations Officer
Ms. Gina M. Mazzariello Chief Legal Officer & Gen. Counsel
Ms. Shauna Horvath Head of Global Marketing
Ms. Debra L. Canner Global Head of HR & CHRO
Dr. Patrick D. Yeramian M.D., MBA, Ph.D. Global Head of Clinical R&D and Chief Medical Officer
Mr. Chris Aiello Head of Canada & GM

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 16.3998
Price-to-Sales TTM: 6725.4844
IPO Date: 2022-01-07
Fiscal Year End: December
Full Time Employees: 237
Back to stocks